• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

杂合子 CFTR p.Gly542* 和 c.2657+5G>A 致儿童胰腺功能不全:病例报告。

Pancreatic Insufficiency in a Child with p.Gly542* and c.2657+5G>A Heterozygote CFTR: A Case Report.

机构信息

Medicial student, Federal University of Fronteira Sul, Chapecó, SC, Brazil.

Post-doctorate in immunology, Federal University of Fronteira Sul, Chapecó, SC, Brazil.

出版信息

Clin Med Res. 2022 Mar;20(1):46-51. doi: 10.3121/cmr.2022.1618. Epub 2022 Feb 7.

DOI:10.3121/cmr.2022.1618
PMID:35131845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9390849/
Abstract

Cystic fibrosis is a monogenic and autosomal recessive disease. It is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene responsible for encoding the CFTR protein. Involvement of the gastrointestinal and respiratory systems is the main clinical manifestation. In this case, we report a heterozygous patient harboring class I (p.Gly542*) and class V (c.2657+5G>A) mutations. The importance of this case report lies in the clinical features because the patient, aged 3 years, presented with early exocrine pancreatic insufficiency, which can be considered atypical, as most individuals with this genotype are pancreatic sufficient or develop pancreatic insufficiency later in life. This report aims at presenting the tests requested that contributed to the patient's diagnosis, as well as at understanding the association between these mutations and their phenotypic presentation. Interpretation of the genotype-phenotype relationship represents a challenge, as genetic analysis alone is not sufficient to clearly predict severity of the disease. This is because the significant phenotypic heterogeneity existing among patients with the same genotype may exert socioeconomic and sociocultural influences, or by the action of modifiers, such as environmental and modifying genes, which can alter the protein's function and exert an impact on the individual's phenotype.

摘要

囊性纤维化是一种单基因常染色体隐性遗传病。它是由编码 CFTR 蛋白的囊性纤维化跨膜电导调节因子基因的突变引起的。胃肠道和呼吸系统的受累是其主要临床表现。在本病例中,我们报告了一名携带 I 类(p.Gly542*)和 V 类(c.2657+5G>A)突变的杂合子患者。本病例报告的重要性在于其临床表现,因为该患者年龄为 3 岁,表现为早期外分泌胰腺功能不全,这可能是非典型的,因为大多数具有这种基因型的个体胰腺功能正常,或在以后的生活中才会发展为胰腺功能不全。本报告旨在介绍有助于患者诊断的检查,并了解这些突变与表型表现之间的关联。对基因型-表型关系的解释是一项挑战,因为仅进行基因分析不足以明确预测疾病的严重程度。这是因为具有相同基因型的患者之间存在显著的表型异质性,可能受到社会经济和社会文化的影响,或者受到修饰因子(如环境和修饰基因)的影响,这些因素可以改变蛋白质的功能并对个体的表型产生影响。

相似文献

1
Pancreatic Insufficiency in a Child with p.Gly542* and c.2657+5G>A Heterozygote CFTR: A Case Report.杂合子 CFTR p.Gly542* 和 c.2657+5G>A 致儿童胰腺功能不全:病例报告。
Clin Med Res. 2022 Mar;20(1):46-51. doi: 10.3121/cmr.2022.1618. Epub 2022 Feb 7.
2
[Genotype and phenotype of gastrointestinal symptoms analysis in children with cystic fibrosis].[囊性纤维化患儿胃肠道症状的基因型与表型分析]
Pol Merkur Lekarski. 2005 Feb;18(104):205-9.
3
Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.囊性纤维化跨膜传导调节因子(CFTR)基因突变在外分泌胰腺中的分子后果。
Gut. 2003 Aug;52(8):1159-64. doi: 10.1136/gut.52.8.1159.
4
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.囊性纤维化跨膜电导调节因子(CFTR)基因突变与胰腺炎。
J Cyst Fibros. 2012 Sep;11(5):355-62. doi: 10.1016/j.jcf.2012.05.001. Epub 2012 Jun 2.
5
Diagnosis of cystic fibrosis.囊性纤维化的诊断。
Clin Rev Allergy Immunol. 2008 Dec;35(3):100-6. doi: 10.1007/s12016-008-8078-x.
6
Novel CFTR mutations in a Korean infant with cystic fibrosis and pancreatic insufficiency.韩国一名患有囊性纤维化和胰腺功能不全的婴儿中新型 CFTR 突变。
J Korean Med Sci. 2010 Jan;25(1):163-5. doi: 10.3346/jkms.2010.25.1.163. Epub 2009 Dec 29.
7
Thirteen cystic fibrosis patients, 12 compound heterozygous and one homozygous for the missense mutation G85E: a pancreatic sufficiency/insufficiency mutation with variable clinical presentation.13名囊性纤维化患者,12名是错义突变G85E的复合杂合子,1名是该突变的纯合子:这是一种具有可变临床表现的胰腺功能充足/不足突变。
J Med Genet. 1996 Oct;33(10):820-2. doi: 10.1136/jmg.33.10.820.
8
Analysis of exocrine pancreatic function in cystic fibrosis: one mild CFTR mutation does not exclude pancreatic insufficiency.
Eur J Clin Invest. 2001 Sep;31(9):796-801. doi: 10.1046/j.1365-2362.2001.00876.x.
9
Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.急性复发性和慢性胰腺炎作为囊性纤维化和囊性纤维化跨膜电导调节因子相关疾病的初始表现。
Pancreas. 2019 Aug;48(7):888-893. doi: 10.1097/MPA.0000000000001350.
10
Disease-modifying genetic factors in cystic fibrosis.囊性纤维化的疾病修饰遗传因素。
Curr Opin Pulm Med. 2018 May;24(3):296-308. doi: 10.1097/MCP.0000000000000479.

本文引用的文献

1
Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.炎症和氧化应激在囊性纤维化相关组织损伤中的作用:CAPE 作为未来的治疗策略。
Mol Cell Biochem. 2022 Jan;477(1):39-51. doi: 10.1007/s11010-021-04263-6. Epub 2021 Sep 16.
2
Sweat Testing and Recent Advances.汗液检测及最新进展
Front Pediatr. 2021 May 4;9:649904. doi: 10.3389/fped.2021.649904. eCollection 2021.
3
Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.囊性纤维化中的过度炎症和气道表面液体脱水:嘌呤能系统作为治疗靶点。
Inflamm Res. 2021 Jun;70(6):633-649. doi: 10.1007/s00011-021-01464-z. Epub 2021 Apr 27.
4
Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function.依伐卡托特可改善携带能产生残留功能的 CFTR 突变的晚期 CF 患者的肺部疾病。
Respir Med. 2020 Sep;171:106073. doi: 10.1016/j.rmed.2020.106073. Epub 2020 Jul 3.
5
Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy.意大利托斯卡纳地区26年囊性纤维化新生儿筛查中假阴性患者的临床和基因特征
Diagnostics (Basel). 2020 Jul 1;10(7):446. doi: 10.3390/diagnostics10070446.
6
The future of cystic fibrosis care: a global perspective.囊性纤维化护理的未来:全球视角。
Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27.
7
The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report.囊性纤维化跨膜电导调节因子调节剂对无呼吸系统症状的复发性胰腺炎囊性纤维化患者的影响:一例报告。
BMC Gastroenterol. 2019 Jul 11;19(1):123. doi: 10.1186/s12876-019-1044-7.
8
Novel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul.在伊斯坦布尔的一家三级囊性纤维化中心发现囊性纤维化中的新突变和缺失。
Pediatr Pulmonol. 2019 Jun;54(6):743-750. doi: 10.1002/ppul.24299. Epub 2019 Apr 2.
9
Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis.依伐卡托CFTR增强剂疗法对囊性纤维化的胰腺表现有效。
Am J Gastroenterol. 2018 Jul;113(7):1058-1059. doi: 10.1038/s41395-018-0123-7. Epub 2018 Jun 11.
10
A Low-Cost and Simple Genetic Screening for Cystic Fibrosis Provided by the Brazilian Public Health System.巴西公共卫生系统提供的低成本和简单的囊性纤维化基因筛查。
J Pediatr. 2018 Aug;199:272-277.e3. doi: 10.1016/j.jpeds.2018.03.047. Epub 2018 May 3.